Bio-Techne/$TECH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bio-Techne
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
- Ticker
- $TECH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,000
- Headquarters
- Minneapolis, United States
- Website
- www.bio-techne.com
Bio-Techne Metrics
BasicAdvanced
$11B
62.54
$1.16
1.28
$0.32
0.44%
Price and volume
Market cap
$11B
Beta
1.28
52-week high
$72.69
52-week low
$43.20
Average daily volume
3.1M
Dividend rate
$0.32
Financial strength
Current ratio
4.547
Quick ratio
2.94
Long term debt to equity
0.13
Total debt to equity
0.137
Dividend payout ratio (TTM)
27.45%
Interest coverage (TTM)
28.51%
Profitability
EBITDA (TTM)
355.054
Gross margin (TTM)
66.24%
Net profit margin (TTM)
14.97%
Operating margin (TTM)
21.21%
Effective tax rate (TTM)
24.44%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
6.26%
Return on equity (TTM)
9.03%
Valuation
Price to earnings (TTM)
62.543
Price to revenue (TTM)
9.313
Price to book
5.37
Price to tangible book (TTM)
13.65
Price to free cash flow (TTM)
42.987
Free cash flow yield (TTM)
2.33%
Free cash flow per share (TTM)
1.688
Dividend yield (TTM)
0.44%
Forward dividend yield
0.44%
Growth
Revenue change (TTM)
-0.38%
Earnings per share change (TTM)
152.17%
3-year revenue growth (CAGR)
2.25%
10-year revenue growth (CAGR)
9.31%
3-year earnings per share growth (CAGR)
-12.97%
10-year earnings per share growth (CAGR)
5.18%
What the Analysts think about Bio-Techne
Analyst ratings (Buy, Hold, Sell) for Bio-Techne stock.
Analyst projections of the future price of Bio-Techne stock.
Bulls say / Bears say
Merck’s agreed $73-a-share cash offer gives shareholders a defined exit value, and Bio-Techne shareholders approved the deal in September. (Bio-Techne)
Diagnostics and Spatial Biology grew 8% organically in Q4 FY26, while its operating margin improved to 11.2% from 6.0%. That points to better momentum in a growth-oriented part of the business. (Bio-Techne)
Large pharma revenue grew by double digits for a sixth consecutive quarter in Q3 FY26, showing resilient demand from an important customer group. (Bio-Techne)
Full-year FY26 revenue was flat, and adjusted EPS was almost unchanged at $1.93 versus $1.92. The latest results offer little evidence of broad-based growth yet. (Bio-Techne)
Protein Sciences, the larger segment, recorded a 1% organic revenue decline for FY26 and its operating margin fell to 41.1% from 42.6%, with the company citing unfavourable volume and product mix. (Bio-Techne)
US academic funding cuts weighed on Q3 sales, while management said healthier biotech funding had not yet translated into broad-based demand. That leaves recovery dependent on customers starting to spend more. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2026.
Bio-Techne Financial Performance
Revenues and expenses
Bio-Techne Earnings Performance
Company profitability
Upcoming events
No upcoming events
Bio-Techne News
AllArticlesVideos
Funds containing Bio-Techne
AllUSDEURGBP
Fund name | Fund size | $TECH weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.3B | 1.13% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.13% |
iShares Healthcare Innovation£DRDR | $1.3B | 1.13% |
Xtrackers S&P 500 Swap£XSPX | $9.7B | 0.31% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.